![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Philip A Levin, Hiep Nguyen, Eric T Wittbrodt & Seoyoung C Kim. (2017) Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity 10, pages 123-139.
Read now
Read now
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst & Sten Madsbad. (2016) Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy 16:4, pages 579-590.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
L. Østergaard, Christian S. Frandsen & S. Madsbad. (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology 9:2, pages 241-265.
Read now
Read now
Stuart A. Ross & Jane Ballantine. (2013) Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes. Current Medical Research and Opinion 29:12, pages 1617-1626.
Read now
Read now
Manfredi Rizzo, Dragana Nikolic, Maciej Banach, Rosaria Vincenza Giglio, Angelo Maria Patti, Vittoria Di Bartolo, Annamaria Tamburello, Antonella Zabbara, Giuseppina Pecoraro, Giuseppe Montalto & Ali A Rizvi. (2013) The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology 8:2, pages 173-181.
Read now
Read now
Articles from other publishers (83)
Yukiko Onishi, Shinichiro Shirabe, Kosei Eguchi, Keiji Nishijima, Toshihiro Sato & Hiroaki Seino. (2023) Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study. Diabetology International.
Crossref
Crossref
Vallo Volke, Urmeli Katus, Annika Johannson, Karolin Toompere, Keiu Heinla, Kertu Rünkorg & Anneli Uusküla. (2022) Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC Endocrine Disorders 22:1.
Crossref
Crossref
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, Takeshi Imaoka & Yutaka Seino. (2022) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology 10:9, pages 623-633.
Crossref
Crossref
Yutaka Seino, Hideaki Miyoshi, Heidrun Bosch Traberg, T V S Divyalasya, Keiji Nishijima & Yasuo Terauchi. (2022) A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. Journal of Diabetes Investigation 13:8, pages 1321-1329.
Crossref
Crossref
Weiting Hu, Rui Song, Rui Cheng, Caihong Liu, Rui Guo, Wei Tang, Jie Zhang, Qian Zhao, Xing Li & Jing Liu. (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 13.
Crossref
Crossref
Takeshi OsonoiMiyoko SaitoYusuke OsonoiSatako DouguchiKensuke OfuchiMakoto Katoh. (2020) Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis. Diabetes Technology & Therapeutics 22:11, pages 828-834.
Crossref
Crossref
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, Srikanth Deenadayalan, Andrea Navarria, Keiji Nishijima, Yutaka Seino, Y Fukushima, Y Hamamoto, A Hisatomi, Y Ide, S Inoue, T Kawada, H Kim, A Kiyosue, K Matoba, O Matsuoka, H Nishimura, M Noguchi, T Osonoi, S Sawada, Y Shibasaki, K Shin & Y Yamada. (2020) Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. The Lancet Diabetes & Endocrinology 8:5, pages 377-391.
Crossref
Crossref
Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, Srikanth Deenadayalan, Andrea Navarria, Mette Gislum, Nobuya Inagaki, T Arisaka, T Asakura, N Azuma, S Fukuda, Y Fukushima, N Harada, S Inoue, H Ishida, H Ishii, S Ishikawa, H Jinnouchi, S Kaneko, K Kanno, M Kato, Y Kato, T Kawada, H Kim, A Kiyosue, O Matsuoka, O Miho, S Nakamoto, S Nakamura, S Nakanishi, H Nishimura, A Numata, T Ohama, T Okabe, F Okuguchi, T Osonoi, T Sasaki, H Seino, K Shin, T Shiraiwa, T Sugiura, S Wada & A Yamauchi. (2020) Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology 8:5, pages 392-406.
Crossref
Crossref
Yi Ming Li, Li Hui Zhang, Xue Jun Li, Bin Zhang, Jia Ning Hou & Nan Wei Tong. (2020) Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. Diabetes Therapy 11:5, pages 1077-1090.
Crossref
Crossref
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu & Koichiro Atsuda. (2019) Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan. Journal of Diabetes Investigation 11:1, pages 96-100.
Crossref
Crossref
Sellami-Mnif Houda, Umehara Toshihiro, Yamazaki Yuriko, Otake Hiroyuki, Matoba Reie, Sakashita Anna & Matsuda Masafumi. (2019) Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost. Diabetology International 11:1, pages 49-56.
Crossref
Crossref
Xu Zhao, Kun Huang, Meijie Zheng & Junting Duan. (2019) Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocrine Disorders 19:1.
Crossref
Crossref
Chuqing Cao, Shuting Yang & Zhiguang Zhou. (2019) GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:2, pages 157-165.
Crossref
Crossref
Chun-Mei Duan, Teng-Fei Wan, Yue Wang & Qing-Wu Yang. (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. Medicine 98:46, pages e17860.
Crossref
Crossref
Yu Hong Chen, Chien-Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang & Wei Qing Wang. (2018) Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes, Obesity and Metabolism 20:9, pages 2121-2130.
Crossref
Crossref
Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, Heidrun Bosch-Traberg & Kohei Kaku. (2018)
Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes:
Post-hoc
analysis of a randomized, 52-week, open-label, parallel-group trial
. Journal of Diabetes Investigation 9:4, pages 831-839.
Crossref
Crossref
Saki Yamamoto, Toshiyuki Hayashi, Makoto Ohara, Satoshi Goto, Jun Sato, Hiroe Nagaike, Ayako Fukase, Nobuko Sato, Munenori Hiromura, Masako Tomoyasu, Noriko Nakanishi, Soushou Lee, Anna Osamura, Takeshi Yamamoto, Tomoyasu Fukui & Tsutomu Hirano. (2018) Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. Diabetes Research and Clinical Practice 140, pages 339-346.
Crossref
Crossref
Yutaka Seino, Yasuo Terauchi, Xiangling Wang, Daisuke Watanabe & Elisabeth Niemoeller. (2017) Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study. Journal of Diabetes Investigation 9:1, pages 108-118.
Crossref
Crossref
Junichi Mukai, Yuta Tsuge, Michiko Yamada, Katsuya Otori & Koichiro Atsuda. (2017) Effects of resistant dextrin for weight loss in overweight adults: a systematic review with a meta-analysis of randomized controlled trials. Journal of Pharmaceutical Health Care and Sciences 3:1.
Crossref
Crossref
Fang Zhang, Lizhi Tang, Yuwei Zhang, Qingguo Lü & Nanwei Tong. (2017) Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Che-Yi Chou, Ying-Tzu Chang, Jia-Lian Yang, Jiun-Yi Wang, Tsui-Er Lee, Ruey-Yun Wang & Chin-Chuan Hung. (2017) Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis. Scientific Reports 7:1.
Crossref
Crossref
Tiansheng Wang, Fei Wang, Junwen Zhou, Huilin Tang & Sharon Giovenale. (2016) Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes/Metabolism Research and Reviews 32:8, pages 843-857.
Crossref
Crossref
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun & Siyan Zhan. (2016) Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLOS ONE 11:5, pages e0154206.
Crossref
Crossref
M. Odawara, J. Miyagawa, N. Iwamoto, Y. Takita, T. Imaoka & T. Takamura. (2016)
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in
J
apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase
III
study
. Diabetes, Obesity and Metabolism 18:3, pages 249-257.
Crossref
Crossref
Kohei Kaku, Arihiro Kiyosue, Yuri Ono, Toshihiko Shiraiwa, Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch‐Traberg & Yutaka Seino. (2015) Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial. Journal of Diabetes Investigation 7:1, pages 76-84.
Crossref
Crossref
Ryota Usui, Daisuke Yabe, Hitoshi Kuwata, Kenta Murotani, Takeshi Kurose & Yutaka Seino. (2015) Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation. Journal of Diabetes and its Complications 29:8, pages 1203-1210.
Crossref
Crossref
Yutaka Seino, Daisuke Yabe, Akane Takami, Elisabeth Niemoeller & Hiroki Takagi. (2015) Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan. Journal of Diabetes and its Complications 29:8, pages 1304-1309.
Crossref
Crossref
E. Araki, N. Inagaki, Y. Tanizawa, T. Oura, M. Takeuchi & T. Imaoka. (2015)
Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in
J
apanese patients with type 2 diabetes: a randomized, open‐label, phase
III
, non‐inferiority study
. Diabetes, Obesity and Metabolism 17:10, pages 994-1002.
Crossref
Crossref
Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm & Thomas P Almdal. (2015) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Xiaoyan Song, Hetang Jia, Yuebo Jiang, Liang Wang, Yan Zhang, Yiming Mu & Yu Liu. (2015) Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Alaaeldin M. K. Bashier, Azza Abdulaziz Khalifa Bin Hussain, Elamin Ibrahim Elamin Abdelgadir, Ahmed Tarig Eltinay, Puja Thadani, Mohamed Elhassan Abdalla, Salah Abusnana & Fatheya F. AlAwadi. (2015) Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Rieko Takano, Masao Yoshida, Masahiro Inoue, Takeshi Honda, Ryutaro Nakashima, Koji Matsumoto, Tatsuya Yano, Tsuneaki Ogata, Nobuaki Watanabe, Masakazu Hirouchi, Tomoko Yoneyama, Shuichiro Ito & Narihiro Toda. (2015) Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Medicinal Chemistry Letters 6:3, pages 266-270.
Crossref
Crossref
Xin-gang Yao, Xin Xu, Gai-hong Wang, Min Lei, Ling-ling Quan, Yan-hua Cheng, Ping Wan, Jin-pei Zhou, Jing Chen, Li-hong Hu & Xu Shen. (2015) BBT improves glucose homeostasis by ameliorating β-cell dysfunction in type 2 diabetic mice. Journal of Endocrinology 224:3, pages 327-341.
Crossref
Crossref
Masanori Emoto, Yasuo Terauchi, Akichika Ozeki, Tomonori Oura, Masakazu Takeuchi & Takeshi Imaoka. (2015) A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocrine Journal 62:12, pages 1101-1114.
Crossref
Crossref
Masao Toyoda, Hiroki Yokoyama, Katsushige Abe, Shuji Nakamura & Daisuke Suzuki. (2014) Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Research and Clinical Practice 106:3, pages 451-457.
Crossref
Crossref
Lesley J. Scott. (2014) Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus. Drugs 74:18, pages 2161-2174.
Crossref
Crossref
Regin Elsa George & Siby Joseph. (2014) A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharmaceutical Journal 22:5, pages 403-410.
Crossref
Crossref
Véronique Raimond, Jean-Michel Josselin & Lise Rochaix. (2014) HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes. PharmacoEconomics 32:9, pages 825-839.
Crossref
Crossref
Y. Seino, A. Takami, G. Boka, E. Niemoeller & D. Raccah. (2014) Pharmacodynamics of the glucagon‐like peptide‐1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes, Obesity and Metabolism 16:8, pages 739-747.
Crossref
Crossref
Apoorva G. UgarkarPremlata K. AmbreEvans C. CoutinhoSantosh NandanRaghuvir R.S. Pissurlenkar. (2014) Extracting structural requirements for activity of GPR119 agonists: a hologram quantitative structure activity relationship (HQSAR) study. Canadian Journal of Chemistry 92:7, pages 670-676.
Crossref
Crossref
Takehiro Kawata, Akira Kanamori, Akira Kubota, Hajime Maeda, Hikaru Amamiya, Masahiko Takai, Hideaki Kaneshige, Fuyuki Minagawa, Kotaro Iemitsu, Mizuki Kaneshiro, Masashi Ishikawa, Hiroshi Takeda, Tetsurou Takuma, Atsuko Mokubo, Hideo Machimura, Mitsuo Obana, Masaaki Miyakawa, Yoshikazu Naka, Yasuo Terauchi, Masao Toyoda, Daisuke Suzuki, Yasushi Tanaka & Ikuro Matsuba. (2013) Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients. Diabetology International 5:2, pages 98-104.
Crossref
Crossref
Jay H. ShubrookJrJr. (2014) Managing Recent-Onset Diabetes: Choosing Durable, Well-Tolerated Therapies and Understanding the Role of Incretin-Based Therapies. Journal of Osteopathic Medicine 114:s52, pages 6-13.
Crossref
Crossref
Antonella Amato, Sara Baldassano, Rosa Liotta, Rosa Serio & Flavia Mulè. (2014) Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. Journal of Endocrinology 221:1, pages 29-37.
Crossref
Crossref
Mette Bohl, Ann Overgaard, Anna Pietraszek & Kjeld Hermansen. (2014) Management of Type 2 diabetes with liraglutide. Diabetes Management 4:2, pages 189-201.
Crossref
Crossref
Joseph M. Tibaldi. (2014) Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes. Advances in Therapy 31:3, pages 289-317.
Crossref
Crossref
Hiroki YokoyamaKoichi HiraoKohei YamaguchiMariko OishiGendai LeeNoriharu YagiHiroshi TakamuraAtsunori Kashiwagi. (2014) Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Japanese Clinical Medicine 5, pages JCM.S16585.
Crossref
Crossref
Xing-Chun Wang. (2014) Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World Journal of Gastroenterology 20:40, pages 14821.
Crossref
Crossref
Taichi Nakamura, Tetsuhide Ito, Masahiko Uchida, Masayuki Hijioka, Hisato Igarashi, Takamasa Oono, Masaki Kato, Kazuhiko Nakamura, Koichi Suzuki, Robert T Jensen & Ryoichi Takayanagi. (2013) PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Laboratory Investigation 94:1, pages 63-78.
Crossref
Crossref
J. E. Schopman, A. C. R. Simon, S. J. M. Hoefnagel, J. B. L. Hoekstra, R. J. P. M. Scholten & F. Holleman. (2014) The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 30:1, pages 11-22.
Crossref
Crossref
Ryota Usui, Daisuke Yabe, Hitoshi Kuwata, Shuichi Fujiwara, Koin Watanabe, Takanori Hyo, Akihiro Yasuhara, Masahiro Iwasaki, Naomi Kitatani, Kyoko Kuwabara, Kayo Yokota, Takeshi Kurose & Yutaka Seino. (2013) Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. Journal of Diabetes Investigation 4:6, pages 585-594.
Crossref
Crossref
M. Monami, S. Genovese & E. Mannucci. (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 15:10, pages 938-953.
Crossref
Crossref
O. J. Phung, E. Schwartzman, R. W. Allen, S. S. Engel & S. N. Rajpathak. (2013) Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabetic Medicine 30:10, pages 1160-1171.
Crossref
Crossref
Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm & Thomas P Almdal. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ronald C.W. Ma & Juliana C.N. Chan. (2013) Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Annals of the New York Academy of Sciences 1281:1, pages 64-91.
Crossref
Crossref
Ryuji Matsushita, Shotaro Taniguchi, Keiichi Matsuzaki, Yoshiyuki Furumatsu, Yumiko Yanagihara, Kazuko Harada, Koujin Nakayama, Kaori Kato, Tomonori Nakashima, Shuji Nakamura & Masanao Nagatomo. (2013) An examination of switching from insulin to glucagon-like peptide-1 analogue liraglutide in hemodialysis patients with type 2 diabetes: A descriptive epidemiology study. Nihon Toseki Igakkai Zasshi 46:9, pages 923-929.
Crossref
Crossref
Daisuke Suzuki, Masao Toyoda, Moritugu Kimura, Masaaki Miyauchi, Naoyuki Yamamoto, Hiroki Sato, Eitaro Tanaka, Yusuke Kuriyama, Han Miyatake, Makiko Abe, Tomoya Umezono & Masafumi Fukagawa. (2013) Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus. Internal Medicine 52:10, pages 1029-1034.
Crossref
Crossref
Takuo Nambu, Yuki Matsuda, Koji Matsuo, Yugo Kanai, Shin Yonemitsu, Seiji Muro & Shogo Oki. (2012) Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin. Journal of Diabetes Investigation 4:1, pages 69-77.
Crossref
Crossref
Yuya Fujishima, Norikazu Maeda, Kana Inoue, Susumu Kashine, Hitoshi Nishizawa, Ayumu Hirata, Junji Kozawa, Tetsuyuki Yasuda, Kohei Okita, Akihisa Imagawa, Tohru Funahashi & Iichiro Shimomura. (2012) Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovascular Diabetology 11:1.
Crossref
Crossref
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Kentaro Ohtoshi, Hideaki Kaneto, Naoto Katakami, Taka‐aki Matsuoka & Iichiro Shimomura. (2012) Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy. Journal of Diabetes Investigation 3:6, pages 510-516.
Crossref
Crossref
Y. Seino, K. W. Min, E. Niemoeller & A. Takami. (2012)
Randomized, double‐blind, placebo‐controlled trial of the once‐daily
GLP
‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (
GetGoal
‐L‐Asia)
. Diabetes, Obesity and Metabolism 14:10, pages 910-917.
Crossref
Crossref
Kenji Negoro, Yasuhiro Yonetoku, Hana Misawa-Mukai, Wataru Hamaguchi, Tatsuya Maruyama, Shigeru Yoshida, Makoto Takeuchi & Mitsuaki Ohta. (2012) Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists. Bioorganic & Medicinal Chemistry 20:17, pages 5235-5246.
Crossref
Crossref
Yutaka Seino, Mads Frederik Rasmussen, Per Clauson & Kohei Kaku. (2012) The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 3:4, pages 388-395.
Crossref
Crossref
Bruce Bode. (2012) An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Research and Clinical Practice 97:1, pages 27-42.
Crossref
Crossref
Junji Kozawa, Kana Inoue, Ryuya Iwamoto, Yukiko Kurashiki, Yukiyoshi Okauchi, Susumu Kashine, Tetsuhiro Kitamura, Norikazu Maeda, Kohei Okita, Hiromi Iwahashi, Tohru Funahashi, Akihisa Imagawa & Iichiro Shimomura. (2012) Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. Journal of Diabetes Investigation 3:3, pages 294-297.
Crossref
Crossref
Baptist Gallwitz, Juan Guzman, Francesco Dotta, Bruno Guerci, Rafael Simó, Bruce R Basson, Andreas Festa, Jacek Kiljański, Hélène Sapin, Michael Trautmann & Guntram Schernthaner. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet 379:9833, pages 2270-2278.
Crossref
Crossref
Yi-Ming Mu, Anoop Misra, John M.F. Adam, Siew Pheng Chan, Francis C.C. Chow, Elaine Cheeay Cunanan, Chaicharn Deerochanawong, Hak Chul Jang, Nguyen Thy Khue, Wayne H.-H. Sheu & Kevin E.K. Tan. (2012) Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors. Diabetes Research and Clinical Practice 95:2, pages 179-188.
Crossref
Crossref
Bruce W Bode. (2012) Design, findings and implications of the liraglutide Phase III clinical trial program. Clinical Investigation 2:1, pages 59-72.
Crossref
Crossref
Caroline M. Perry. (2011) Liraglutide. Drugs 71:17, pages 2347-2373.
Crossref
Crossref
Kohei Kaku, Mads Frederik Rasmussen, Tomoyuki Nishida & Yutaka Seino. (2011) Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. Journal of Diabetes Investigation 2:6, pages 441-447.
Crossref
Crossref
Yutaka MoriYukiko TaniguchiKazunori SezakiJunichi YokoyamaKazunori Utsunomiya. (2011) Liraglutide Narrows the Range of Circadian Glycemic Variations in Japanese Type 2 Diabetes Patients and Nearly Flattens These Variations in Drug-Naive Type 2 Diabetes Patients: A Continuous Glucose Monitoring–Based Study. Diabetes Technology & Therapeutics 13:11, pages 1139-1144.
Crossref
Crossref
Kyeong-Hye Jeong & Bong Kyu Yoo. (2011) The efficacy and safety of liraglutide. International Journal of Clinical Pharmacy 33:5, pages 740-749.
Crossref
Crossref
Yutaka Seino, Mads Frederik Rasmussen, Tomoyuki Nishida & Kohei Kaku. (2011) Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. Journal of Diabetes Investigation 2:4, pages 280-286.
Crossref
Crossref
Kohei Kaku. (2011) Liraglutide for the treatment of diabetes mellitus in Japan. Diabetes Management 1:4, pages 451-463.
Crossref
Crossref
Gina J. Ryan, Karla T. Foster & Lynetta Johnson Jobe. (2011) Review of the Therapeutic Uses of Liraglutide. Clinical Therapeutics 33:7, pages 793-811.
Crossref
Crossref
Takashi Kadowaki, Mitsuyoshi Namba, Takeshi Imaoka, Ayuko Yamamura, Wakana Goto, Marilyn K. Boardman & Hideaki Sowa. (2011) Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. Journal of Diabetes Investigation 2:3, pages 210-217.
Crossref
Crossref
Laszlo HegedüsAlan C. MosesMilan ZdravkovicTu Le ThiGilbert H. Daniels. (2011) GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide. The Journal of Clinical Endocrinology & Metabolism 96:3, pages 853-860.
Crossref
Crossref
Daisuke YabeYutaka Seino. (2011) Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. Clinical Medicine Insights: Endocrinology and Diabetes 4, pages CMED.S5976.
Crossref
Crossref
Shigeru Yoshida, Takahide Ohishi, Tetsuo Matsui, Hirotsugu Tanaka, Hiroyuki Oshima, Yasuhiro Yonetoku & Masayuki Shibasaki. (2010) Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochemical and Biophysical Research Communications 402:2, pages 280-285.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:11, pages i-xii.
Crossref
Crossref
Shigeru Yoshida, Takahide Ohishi, Tetsuo Matsui & Masayuki Shibasaki. (2010) Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochemical and Biophysical Research Communications 400:3, pages 437-441.
Crossref
Crossref
Yutaka Seino, Mitsuo Fukushima & Daisuke Yabe. (2010) GIP and GLP-1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation 1:1-2, pages 8-23.
Crossref
Crossref
Hiroshi Sugii, Yoriko Matsumura, Akihiro Inoue, Hiroaki Horigome, Katsuhiro Matsuzaki & Akane Shimizu. (2010) Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza®). Folia Pharmacologica Japonica 136:4, pages 233-241.
Crossref
Crossref